Since romidepsin can significantly increase anti-CD20 CAR-expanded peripheral blood NK cells (exPBNK) in vitro cytotoxicity through NKG2D by inducing the expression of NKG2D ligands MICA/B in both rituximab-sensitive and rituximab-resistant BL cells [161]. The gene discussed is KLRK1; the disease is Burkitt lymphoma.